Japan: no added use for Nexavar, Alimta
Japan's Central Social Insurance Medical Council (Chuikyo) has decided to exclude an additional indication of inoperable hepatic cell cancer for Nexavar (sorafenib) and of inoperable progressive and recurrent non-small cell lung cancer for Alimta (pemetrexed), from an application for lump-sum reimbursement in hospitals adopting the Diagnostic Procedure Combination reimbursement system. Those additional indications were approved by Japan's Ministry of Health, Labor and Welfare on May 20.
The criteria to admit or exclude an expensive drug from the DPC in a certain situation is because of its excessive discrepancy between the National Health Insurance drug cost and the DPC reimbursement price for an existing treatment, to prevent a heavy financial burden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze